As an exemplar, a recent double-blind, placebo-controlled randomized clinical trial examined the effect of ezogabine, a potassium channel opener, on cortical and peripheral excitability in a cohort of ALS patients [134]. This evidence concerns the gene KCNA3 and amyotrophic lateral sclerosis.